Faricimab (Vabysmo)


 CADTH recommends that Vabysmo be reimbursed by public drug plans for the treatment of diabetic macular edema (DME) if certain conditions are met.
 should covered to treat patients with DME provided it is a similar patient population and in way other anti–vascular endothelial growth factor (VEGF) drugs currently adult DME.
 only prescribed an ophthalmologist experience managing cost not more than least costly anti-VEGF